Show simple item record

dc.contributor.authorAltadill, Tatiana
dc.contributor.authorDowdy, Tyrone M.
dc.contributor.authorGill, Kirandeep
dc.contributor.authorReques, Armando
dc.contributor.authorMenon, Smrithi S.
dc.contributor.authorMoiola, Cristian P.
dc.contributor.authorLopez-Gil, Carlos
dc.contributor.authorColl, Eva
dc.contributor.authorMatias-Guiu, Xavier
dc.contributor.authorCabrera, Silvia
dc.contributor.authorGarcia, Angel
dc.contributor.authorReventos, Jaume
dc.contributor.authorW. Byers, Stephen
dc.contributor.authorGil-Moreno, Antonio
dc.contributor.authorCheema, Amrita K.
dc.contributor.authorColas, Eva
dc.description.abstractEndometrial cancer (EC) remains the most common malignancy of the genital tract among women in developed countries. Although much research has been performed at genomic, transcriptomic and proteomic level, there is still a significant gap in the metabolomic studies of EC. In order to gain insights into altered metabolic pathways in the onset and progression of EC carcinogenesis, we used high resolution mass spectrometry to characterize the metabolomic and lipidomic profile of 39 human EC and 17 healthy endometrial tissue samples. Several pathways including lipids, Kynurenine pathway, endocannabinoids signaling pathway and the RNA editing pathway were found to be dysregulated in EC. The dysregulation of the RNA editing pathway was further investigated in an independent set of 183 human EC tissues and matched controls, using orthogonal approaches. We found that ADAR2 is overexpressed in EC and that the increase in expression positively correlates with the aggressiveness of the tumor. Furthermore, silencing of ADAR2 in three EC cell lines resulted in a decreased proliferation rate, increased apoptosis, and reduced migration capabilities in vitro. Taken together, our results suggest that ADAR2 functions as an oncogene in endometrial carcinogenesis and could be a potential target for improving EC treatment strategies.ca_ES
dc.description.sponsorshipThis work was supported by the Spanish Ministry of Health (RD12/0036/0035), the Spanish Ministry of Economy and Competitivy (PI14/02043), the AECC (Grupos Estables de Investigacion 2011 - AECC- GCB 110333 REVE), the Fundació La Marató TV3 (2/C/2013), the CIRIT Generalitat de Catalunya (2014 SGR 1330) and the European Commission, 7th Framework Program, IRSES (PROTBIOFLUID –269285) – Belgium. Te Spanish Ministry of Economy and Competitiveness (IJCI-2015-25000) granted Dr. Colás and and the AGAUR Generalitat de Catalunya (2015FI_B00703) granted Tatiana Altadill. Te authors would like to acknowledge the Proteomics and Metabolomics Shared Resource partially supported by Cancer Center Support Grant NIH/NCI grant P30-CA051008. Te Institut de Salud Carlos III (FIS (PI13/01701)) also supported this project. Tissue samples were obtained with the support of “Xarxa Catalana de Bancs de Tumors” and “Plataforma de Biobancos” ISCIII (PT13/0010/0014).
dc.publisherNature Publishing Groupca_ES
dc.relation.isformatofReproducció del document publicat a
dc.relation.ispartofScientific Reports, 2017, vol. 7, núm. 8803, p. 1-13ca_ES
dc.rightscc-by (c) Altadill et al., 2017ca_ES
dc.titleMetabolomic and lipidomic profiling identifies the role of the RNA editing pathway in endometrial carcinogenesisca_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by (c) Altadill et al., 2017
Except where otherwise noted, this item's license is described as cc-by (c) Altadill et al., 2017